Jazz Pharmaceuticals PLC

詳細情報 Jazz Pharmaceuticals PLC 企業名

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

企業情報

企業コードJAZZ

会社名Jazz Pharmaceuticals PLC

上場日Jan 18, 2012

最高経営責任者「CEO」Ms. Renee D. Gala

従業員数2800

証券種類Ordinary Share

決算期末Jan 18

本社所在地Fifth Floor, Waterloo Exchange

都市DUBLIN

証券取引所NASDAQ Global Select Consolidated

国Ireland

郵便番号- -

電話番号35316347800

ウェブサイトhttps://www.jazzpharma.com/

企業コードJAZZ

上場日Jan 18, 2012

最高経営責任者「CEO」Ms. Renee D. Gala

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

313.31K

-6.46%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Mr. Rick E. Winningham

Lead Independent Director

10.66K

+19.00%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

313.31K

-6.46%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

他の

129.09M

14.38%

地域別USD

会社名

収益

比率

United States

797.95M

88.87%

Europe

83.61M

9.31%

All Others

16.29M

1.81%

事業別

地域別

事業別USD

会社名

収益

比率

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

他の

129.09M

14.38%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

他の

68.80%

株主統計

比率

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

他の

68.80%

種類

株主統計

比率

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

34.72%

Hedge Fund

8.97%

Research Firm

3.43%

Individual Investor

3.08%

Pension Fund

2.83%

Venture Capital

1.89%

Bank and Trust

0.91%

Sovereign Wealth Fund

0.14%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

2023Q1

1207

61.36M

96.91%

-3.79M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

5.99M

9.91%

-18.47K

-0.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.21M

8.61%

-33.38K

-0.64%

Mar 31, 2025

LSV Asset Management

2.47M

4.08%

-64.88K

-2.56%

Mar 31, 2025

Capital World Investors

1.93M

3.19%

+4.45K

+0.23%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.33M

3.85%

+293.36K

+14.42%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.25%

-2.23K

-0.11%

Mar 31, 2025

EcoR1 Capital, LLC

1.71M

2.82%

--

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

1.33M

2.2%

+391.66K

+41.69%

Mar 31, 2025

JP Morgan Asset Management

1.50M

2.48%

+71.69K

+5.01%

Mar 31, 2025

Columbia Threadneedle Investments (US)

1.35M

2.24%

-136.12K

-9.14%

Mar 31, 2025

詳細を見る

128.300USD

Jazz Pharmaceuticals PLC

128.300

概要

企業名

金融

分析